25-hydroxycholesterol-3-sulfate

Product Name25-hydroxycholesterol-3-sulfate
CAS884905-07-1
MFC27H46O5S
MW482.72
EINECS
MOL File884905-07-1.mol

Chemical Properties

Density	1.16±0.1 g/cm3(Predicted)
storage temp.	-20°C
pka	-3.51±0.18(Predicted)
form	powder

Usage And Synthesis

Uses

25-hydroxycholesterol-3-sulfate has been used to induce anti-inflammatory responses and understand its effect on lymphocyte migration. It has also been used as an oxysterol sulfate standard in mass spectroscopy and liquid chromatography methods.

Biological Activity

25-hydroxycholesterol-3-sulfate (25OHC3S) is involved in lipid homeostasis in liver and is a lipid metabolism regulator. 25OHC3S acts on liver X receptor (LXR) and sterol regulatory element-binding protein (SREBP) and inhibits cholesterol synthesis by downregulating enzymes of the biosynthesis pathway in hepatocytes and macrophages. It also acts an agonist for peroxisome proliferator-activated receptor γ (PPAR-γ) and modulates the nuclear factor K-light-chain-enhancer (NF-KB) based inflammatory response. 25OHC3S modulates tumor necrosis factor α (TNFα)-induced inflammatory response in hepatocytes.

in vivo

Larsucosterol (DUR-928; 25 mg/kg; i.p.; twice in 14 hours; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) reduces serum lipid levels in mice fed a high-fat diet^[3].
Larsucosterol (25 mg/kg; i.p.; twice in 14 hours; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) suppressed the expression of the genes and inhibits ABCA1 expressionde. Larsucosterolcreases nuclear SREBP-1 Protein levels and cytoplasmic FAS and ACC1 protein levels in liver tissue^[3].
Larsucosterol (25 mg/kg; i.p.; once every 3 days for 6 weeks; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) protects the liver from injury by suppressing hepatic inflammation^[3].

Animal Model:	Female C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model^[3]
Dosage:	25 mg/kg
Administration:	Intraperitoneal injection; once every 3 days for 6 weeks
Result:	Decreased plasma cholesterol levels. Reduced serum alkaline phosphatase, ALT, and AST levels.

Animal Model:	Female C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model^[3]
Dosage:	25 mg/kg
Administration:	Intraperitoneal injection; twice in 14 hours
Result:	Decreased plasma TG, CHOL, and HDL-C by 40, 15, and 20%, respectively. Reduced the mRNA levels of SREBP-1c, ACC1, and FAS by 46, 57, and 49%, respectively. Suppressed ABCA1 expression. Suppressed nuclear SREBP-1, cytoplasmic ACC1, and FAS protein levels by 74, 58, and 47%, respectively.

25-hydroxycholesterol-3-sulfate Supplier

Send Inquriy